Filed: 8/14/2024ACC: 0001937964-24-000005
📋 What this filing means
ARTIA GLOBAL PARTNERS LP filed this quarterly 13F‑HR report disclosing 46 equity positions with a total reported market value of $517.33M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
46
Positions
$517.33M
Total AUM (reported)
5.61M
Total Shares
Allocation by class
COM$330.96M64.0%
ADR$142.99M27.6%
SPONSORED ADR$22.40M4.3%
COM PAR $.01$10.95M2.1%
COM NEW$4.57M0.9%
SPONSORED ADS$1.89M0.4%
SPON ADS$1.52M0.3%
Portfolio Concentration
Top 3$250.47M48.4%
4–10$170.11M32.9%
11–25$72.81M14.1%
Rest$23.93M4.6%
Top 3 weight
48.4%
Top 10 weight
81.3%
Voting Authority Distribution
Total shares with voting rights: 5.61M
Sole
Full voting authority
5.61M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole46
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings46
Rows:
NOVO-NORDISK A S
SOLEShares691.74K
TypeSH
Market value$98.74M
19.09%
Sole
691.74K
Shared
0.00
None
0.00
ELI LILLY & CO
SOLEShares92.59K
TypeSH
Market value$83.83M
16.20%
Sole
92.59K
Shared
0.00
None
0.00
ELI LILLY & CO
SOLEShares75K
TypeSH
Market value$67.90M
13.13%
Sole
75K
Shared
0.00
None
0.00
MERCK & CO INC
SOLEShares442.50K
TypeSH
Market value$54.78M
10.59%
Sole
442.50K
Shared
0.00
None
0.00
NOVO-NORDISK A S
SOLEShares310K
TypeSH
Market value$44.25M
8.55%
Sole
310K
Shared
0.00
None
0.00
VIKING THERAPEUTICS INC
SOLEShares452.98K
TypeSH
Market value$24.01M
4.64%
Sole
452.98K
Shared
0.00
None
0.00
ASTRAZENECA PLC
SOLEShares190.75K
TypeSH
Market value$14.88M
2.88%
Sole
190.75K
Shared
0.00
None
0.00
INTRA-CELLULAR THERAPIES INC
SOLEShares216.52K
TypeSH
Market value$14.83M
2.87%
Sole
216.52K
Shared
0.00
None
0.00
VERTEX PHARMACEUTICALS INC
SOLEShares18.90K
TypeSH
Market value$8.86M
1.71%
Sole
18.90K
Shared
0.00
None
0.00
ALNYLAM PHARMACEUTICALS INC
SOLEShares35K
TypeSH
Market value$8.51M
1.64%
Sole
35K
Shared
0.00
None
0.00
VIKING THERAPEUTICS INC
SOLEShares150K
TypeSH
Market value$7.95M
1.54%
Sole
150K
Shared
0.00
None
0.00
INSMED INC
SOLEShares110K
TypeSH
Market value$7.37M
1.42%
Sole
110K
Shared
0.00
None
0.00
AXSOME THERAPEUTICS INC
SOLEShares87.85K
TypeSH
Market value$7.07M
1.37%
Sole
87.85K
Shared
0.00
None
0.00
ARGENX SE
SOLEShares15.14K
TypeSH
Market value$6.51M
1.26%
Sole
15.14K
Shared
0.00
None
0.00
NEUROCRINE BIOSCIENCES INC
SOLEShares45K
TypeSH
Market value$6.20M
1.20%
Sole
45K
Shared
0.00
None
0.00
VAXCYTE INC
SOLEShares76.25K
TypeSH
Market value$5.76M
1.11%
Sole
76.25K
Shared
0.00
None
0.00
PROTAGONIST THERAPEUTICS INC
SOLEShares124.44K
TypeSH
Market value$4.31M
0.83%
Sole
124.44K
Shared
0.00
None
0.00
DYNE THERAPEUTICS INC
SOLEShares119.49K
TypeSH
Market value$4.22M
0.82%
Sole
119.49K
Shared
0.00
None
0.00
SOLENO THERAPEUTICS INC
SOLEShares94.42K
TypeSH
Market value$3.85M
0.74%
Sole
94.42K
Shared
0.00
None
0.00
CRINETICS PHARMACEUTICALS IN
SOLEShares85.77K
TypeSH
Market value$3.84M
0.74%
Sole
85.77K
Shared
0.00
None
0.00
INSMED INC
SOLEShares53.44K
TypeSH
Market value$3.58M
0.69%
Sole
53.44K
Shared
0.00
None
0.00
OCULAR THERAPEUTIX INC
SOLEShares500K
TypeSH
Market value$3.42M
0.66%
Sole
500K
Shared
0.00
None
0.00
IONIS PHARMACEUTICALS INC
SOLEShares62.48K
TypeSH
Market value$2.98M
0.58%
Sole
62.48K
Shared
0.00
None
0.00
MERUS N V
SOLEShares50.17K
TypeSH
Market value$2.97M
0.57%
Sole
50.17K
Shared
0.00
None
0.00
CELLDEX THERAPEUTICS INC NEW
SOLEShares75.30K
TypeSH
Market value$2.79M
0.54%
Sole
75.30K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
NOVO-NORDISK A SSOLE | ADR | 691.74K | SH | $98.74M 19.09% | 691.74K | 0.00 | 0.00 |
ELI LILLY & COSOLE | COM | 92.59K | SH | $83.83M 16.20% | 92.59K | 0.00 | 0.00 |
ELI LILLY & COSOLE | COM | 75K | SH | $67.90M 13.13% | 75K | 0.00 | 0.00 |
MERCK & CO INCSOLE | COM | 442.50K | SH | $54.78M 10.59% | 442.50K | 0.00 | 0.00 |
NOVO-NORDISK A SSOLE | ADR | 310K | SH | $44.25M 8.55% | 310K | 0.00 | 0.00 |
VIKING THERAPEUTICS INCSOLE | COM | 452.98K | SH | $24.01M 4.64% | 452.98K | 0.00 | 0.00 |
ASTRAZENECA PLCSOLE | SPONSORED ADR | 190.75K | SH | $14.88M 2.88% | 190.75K | 0.00 | 0.00 |
INTRA-CELLULAR THERAPIES INCSOLE | COM | 216.52K | SH | $14.83M 2.87% | 216.52K | 0.00 | 0.00 |
VERTEX PHARMACEUTICALS INCSOLE | COM | 18.90K | SH | $8.86M 1.71% | 18.90K | 0.00 | 0.00 |
ALNYLAM PHARMACEUTICALS INCSOLE | COM | 35K | SH | $8.51M 1.64% | 35K | 0.00 | 0.00 |
VIKING THERAPEUTICS INCSOLE | COM | 150K | SH | $7.95M 1.54% | 150K | 0.00 | 0.00 |
INSMED INCSOLE | COM PAR $.01 | 110K | SH | $7.37M 1.42% | 110K | 0.00 | 0.00 |
AXSOME THERAPEUTICS INCSOLE | COM | 87.85K | SH | $7.07M 1.37% | 87.85K | 0.00 | 0.00 |
ARGENX SESOLE | SPONSORED ADR | 15.14K | SH | $6.51M 1.26% | 15.14K | 0.00 | 0.00 |
NEUROCRINE BIOSCIENCES INCSOLE | COM | 45K | SH | $6.20M 1.20% | 45K | 0.00 | 0.00 |
VAXCYTE INCSOLE | COM | 76.25K | SH | $5.76M 1.11% | 76.25K | 0.00 | 0.00 |
PROTAGONIST THERAPEUTICS INCSOLE | COM | 124.44K | SH | $4.31M 0.83% | 124.44K | 0.00 | 0.00 |
DYNE THERAPEUTICS INCSOLE | COM | 119.49K | SH | $4.22M 0.82% | 119.49K | 0.00 | 0.00 |
SOLENO THERAPEUTICS INCSOLE | COM | 94.42K | SH | $3.85M 0.74% | 94.42K | 0.00 | 0.00 |
CRINETICS PHARMACEUTICALS INSOLE | COM | 85.77K | SH | $3.84M 0.74% | 85.77K | 0.00 | 0.00 |
INSMED INCSOLE | COM PAR $.01 | 53.44K | SH | $3.58M 0.69% | 53.44K | 0.00 | 0.00 |
OCULAR THERAPEUTIX INCSOLE | COM | 500K | SH | $3.42M 0.66% | 500K | 0.00 | 0.00 |
IONIS PHARMACEUTICALS INCSOLE | COM | 62.48K | SH | $2.98M 0.58% | 62.48K | 0.00 | 0.00 |
MERUS N VSOLE | COM | 50.17K | SH | $2.97M 0.57% | 50.17K | 0.00 | 0.00 |
CELLDEX THERAPEUTICS INC NEWSOLE | COM NEW | 75.30K | SH | $2.79M 0.54% | 75.30K | 0.00 | 0.00 |
Page 1 of 2